drugset / Trial / NCT03286296
LZM009 to Treat Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
To assess the safety and tolerability of IV administered LZM009 in subjects with advanced solid tumors who have progressed or are non-responsive to available therapies.
Timeline
- Start
- 2017-08-21
- Primary completion
- 2019-03-06
- Completion
- 2019-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LZM009 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | LZM009 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | LZM009 | Monoclonal antibody | 10 mg/kg | Intravenous |